Abstract
Activation of soluble guanylate cyclase by nitric oxide (NO) controls signaling pathways that play critical roles in normal vascular physiology and in the pathogenesis of cardiovascular disease. We have identified the secreted protein thrombospondin-1 as a key regulator of NO signaling. Thrombospondin-1 limits the angiogenic activity of NO in endothelial cells, its vasodilator activity in vascular smooth muscle, and its antithrombotic activity in platelets. Loss of either thrombospondin-1 or its receptor CD47 in transgenic mice results in hyperdynamic responses to NO and reveals the importance of this pathway in normal physiology. Thrombospondin-1 and CD47 null mice show improved abilities to respond to ischemic stress, suggesting that therapeutic targeting of this pathway could benefit patients with a variety of ischemic conditions. We review the preclinical development of therapeutics targeting thrombospondin-1 or CD47 for improving survival of fixed ischemia, ischemia due to aging and peripheral vascular disease, and skin grafting.
Keywords: Ischemic injury, tissue perfusion, angiogenesis, hemostasis, blood flow, nitric oxide, vascular smooth muscle, platelets
Current Drug Targets
Title: Enhancing Cardiovascular Dynamics by Inhibition of Thrombospondin- 1/CD47 Signaling
Volume: 9 Issue: 10
Author(s): Jeff S. Isenberg, William A. Frazier, Murali C. Krishna, David A. Wink and David D. Roberts
Affiliation:
Keywords: Ischemic injury, tissue perfusion, angiogenesis, hemostasis, blood flow, nitric oxide, vascular smooth muscle, platelets
Abstract: Activation of soluble guanylate cyclase by nitric oxide (NO) controls signaling pathways that play critical roles in normal vascular physiology and in the pathogenesis of cardiovascular disease. We have identified the secreted protein thrombospondin-1 as a key regulator of NO signaling. Thrombospondin-1 limits the angiogenic activity of NO in endothelial cells, its vasodilator activity in vascular smooth muscle, and its antithrombotic activity in platelets. Loss of either thrombospondin-1 or its receptor CD47 in transgenic mice results in hyperdynamic responses to NO and reveals the importance of this pathway in normal physiology. Thrombospondin-1 and CD47 null mice show improved abilities to respond to ischemic stress, suggesting that therapeutic targeting of this pathway could benefit patients with a variety of ischemic conditions. We review the preclinical development of therapeutics targeting thrombospondin-1 or CD47 for improving survival of fixed ischemia, ischemia due to aging and peripheral vascular disease, and skin grafting.
Export Options
About this article
Cite this article as:
Isenberg S. Jeff, Frazier A. William, Krishna C. Murali, Wink A. David and Roberts D. David, Enhancing Cardiovascular Dynamics by Inhibition of Thrombospondin- 1/CD47 Signaling, Current Drug Targets 2008; 9 (10) . https://dx.doi.org/10.2174/138945008785909338
DOI https://dx.doi.org/10.2174/138945008785909338 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Current Drug Targets Hypertension: Basics Concepts and the Evolving Role of Novel Treatments
Current Hypertension Reviews Gene-Activation Mechanisms in the Regression of Atherosclerosis, Elimination of Diabetes Type 2, and Prevention of Dementia
Current Molecular Medicine Intracellular Redox Signaling as Therapeutic Target for Novel Antiviral Strategy
Current Pharmaceutical Design Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine Neonatal Hypertension: An Underdiagnosed Condition, A Review Article
Current Hypertension Reviews The Role of (Modified) Lipoproteins in Vascular Function: A Duet Between Monocytes and the Endothelium
Current Medicinal Chemistry Psychobiome Feeding Mind: Polyphenolics in Depression and Anxiety
Current Topics in Medicinal Chemistry Diagnostic Tools for Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Oxidative Stress in Atherosclerosis Development: The Central Role of LDL and Oxidative Burst
Endocrine, Metabolic & Immune Disorders - Drug Targets Vascular Oxidative Stress: A Key Factor in the Development of Hypertension Associated with Ethanol Consumption
Current Hypertension Reviews miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Placental Hypoxia Developed During Preeclampsia Induces Telocytes Apoptosis in Chorionic Villi Affecting The Maternal-Fetus Metabolic Exchange
Current Stem Cell Research & Therapy The Role of Statins in Oxidative Stress and Cardiovascular Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Plant Sterols and Stanols in the Treatment of Dyslipidemia: New Insights into Targets and Mechanisms Related to Cardiovascular Risk
Current Pharmaceutical Design